Not yet recruitingPhase 2NCT06429397

Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma

Studying Hereditary pheochromocytoma-paraganglioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Principal Investigator
Shengjie Guo, Doctor
Sun Yat-sen University
Intervention
Anlotinib and Benmelstobart(drug)
Enrollment
22 target
Eligibility
18-75 years · All sexes
Timeline
20252027

Study locations (1)

Collaborators

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06429397 on ClinicalTrials.gov

Other trials for Hereditary pheochromocytoma-paraganglioma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary pheochromocytoma-paraganglioma

← Back to all trials